NCT06775860

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of Oral ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 552 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	ICP-332 Tablets	ICP-332 will be administered as tablet
DRUG	ICP-332 Placebo Tablets	ICP-332 Placebo will be administered as tablet

Timeline

• Start date: 2024-11-14
• Primary completion: 2026-11-25
• Completion: 2026-12-25
• First posted: 2025-01-15
• Last updated: 2025-09-08

Locations

62 sites across 1 country: China